<article title='Chloramphenicol'><paragraph><template><target>Drugbox</target><arg name="Watchedfields"><space/>changed
</arg><arg name="verifiedrevid"><space/>443513464
</arg><arg name="drug_name"><space/>Chloramphenicol (<small>[[International Nonproprietary Name|INN]]</small>)
</arg><arg name="IUPAC_name"><space/>2,2-dichloro-N-[1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide
</arg><arg name="image"><space/>Chloramphenicol-2D-skeletal.svg
</arg><arg name="image2"><space/>Chloramphenicol-3D-vdW.png

<space/></arg><arg name="tradename"><space/>Pentamycetin, Chloromycetin<ref name</arg><arg name="Drugs.com"><space/>{{drugs.com|monograph|chloramphenicol}}
</arg><arg name="MedlinePlus"><space/>a608008
</arg><arg name="licence_US"><space/>Chloramphenicol
</arg><arg name="pregnancy_AU"><space/>A
</arg><arg name="pregnancy_US"><space/>C
</arg><arg name="legal_AU"><space/>S4
</arg><arg name="legal_CA"><space/>Rx-only
</arg><arg name="legal_UK"><space/>POM
</arg><arg name="legal_US"><space/>Rx-only
</arg><arg name="routes_of_administration"><space/>[[Topical]] ([[eye drops]]), by, [[intravenous therapy|IV]], [[intramuscular injection|IM]]

<space/></arg><arg name="bioavailability"><space/>75–90%
</arg><arg name="protein_bound"><space/>60%
</arg><arg name="metabolism"><space/>[[Liver]]
</arg><arg name="elimination_half-life"><space/>1.6-3.3 hours
</arg><arg name="excretion"><space/>[[Kidney]] (5-15%), faeces (4%)

<space/></arg><arg name="CAS_number_Ref"><space/>{{cascite|correct|??}}
</arg><arg name="CAS_number"><space/>56-75-7
</arg><arg name="ATC_prefix"><space/>D06
</arg><arg name="ATC_suffix"><space/>AX02
</arg><arg name="ATC_supplemental"><space/>{{ATC|D10|AF03}} {{ATC|G01|AA05}} {{ATC|J01|BA01}} {{ATC|S01|AA01}} {{ATC|S02|AA01}} {{ATC|S03|AA08}} {{ATCvet|J51|BA01}}
</arg><arg name="ChEBI_Ref"><space/>{{ebicite|correct|EBI}}
</arg><arg name="ChEBI"><space/>17698
</arg><arg name="PubChem"><space/>298
</arg><arg name="DrugBank_Ref"><space/>{{drugbankcite|correct|drugbank}}
</arg><arg name="DrugBank"><space/>DB00446
</arg><arg name="ChemSpiderID_Ref"><space/>{{chemspidercite|correct|chemspider}}
</arg><arg name="ChemSpiderID"><space/>5744
</arg><arg name="UNII_Ref"><space/>{{fdacite|correct|FDA}}
</arg><arg name="UNII"><space/>66974FR9Q1
</arg><arg name="KEGG_Ref"><space/>{{keggcite|correct|kegg}}
</arg><arg name="KEGG"><space/>D00104
</arg><arg name="ChEMBL_Ref"><space/>{{ebicite|correct|EBI}}
</arg><arg name="ChEMBL"><space/>130

<space/></arg><arg name="C">11<space/></arg><arg name="H">12<space/></arg><arg name="Cl">2<space/></arg><arg name="N">2<space/></arg><arg name="O">5
</arg><arg name="molecular_weight"><space/>323.1320 g/mol
</arg><arg name="smiles"><space/>c1cc(ccc1[C@H]([C@@H](CO)NC(</arg><arg name="InChI"><space/>1/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)/t8-,9-/m1/s1
</arg><arg name="StdInChI_Ref"><space/>{{stdinchicite|correct|chemspider}}
</arg><arg name="StdInChI"><space/>1S/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)/t8-,9-/m1/s1
</arg><arg name="StdInChIKey_Ref"><space/>{{stdinchicite|correct|chemspider}}
</arg><arg name="StdInChIKey"><space/>WIIZWVCIJKGZOK-RKDXNWHRSA-N
</arg></template></paragraph><preblock><preline><bold>Chloramphenicol</bold><space/>is an<space/><link><target>antibiotic</target></link><space/>useful for the treatment of a number of<space/><link><target>bacterial</target></link><space/>infections.<extension extension_name='ref' name="AHFS2015"><template><target>cite web</target><arg name="title">Chloramphenicol</arg><arg name="url">http://www.drugs.com/monograph/chloramphenicol.html</arg><arg name="publisher">The American Society of Health-System Pharmacists</arg><arg name="accessdate">Aug 1, 2015</arg></template></extension><space/>This includes<space/><link><target>meningitis</target></link>,<space/><link><target>plague (disease)</target><part>plague</part></link>,<space/><link><target>cholera</target></link>, and<space/><link><target>typhoid fever</target></link>. Its use is only recommended when safer antibiotics cannot be used. Monitoring both blood levels of the medication and blood cell levels every two days is recommended during treatment.<extension extension_name='ref' name="AHFS2015"></extension><space/>It is available intravenously, by mouth, and as an eye ointment.<extension extension_name='ref' name="Wood2009"><template><target>cite book</target><arg name="last1">Woods</arg><arg name="first1">Adrienne L.</arg><arg name="title">Delmar nurse's drug handbook.</arg><arg name="date">2008</arg><arg name="publisher">Delmar</arg><arg name="location">Clifton Park, N.Y.</arg><arg name="isbn">9781428361065</arg><arg name="page">296</arg><arg name="edition">2009</arg><arg name="url">https://books.google.ca/books?id</arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="author1">Truven Health Micromedex</arg><arg name="title">chloramphenicol (Oral route, Intravenous route, Injection route)</arg><arg name="url">http://www.drugs.com/cons/chloramphenicol-oral-intravenous-injection.html</arg><arg name="accessdate">26 August 2015</arg></template></extension></preline></preblock><preblock><preline>Common side effects include<space/><link><target>bone marrow suppression</target></link>, nausea, and diarrhea. The bone marrow suppression may result in death. To reduce the risk of side effects treatment duration should be as short as possible. In those with liver or kidney problems dosing may require decreasing. In young children a condition known as<space/><link><target>gray baby syndrome</target></link><space/>may occur which results in a swollen stomach and low blood pressure.<extension extension_name='ref' name="AHFS2015"></extension><space/>Its use near the end of pregnancy and during breastfeeding is typically not recommended.<extension extension_name='ref'><template><target>cite web</target><arg name="title">Chloramphenicol Pregnancy and Breastfeeding Warnings</arg><arg name="url">http://www.drugs.com/pregnancy/chloramphenicol.html</arg><arg name="website">Multum Information Services</arg><arg name="accessdate">26 August 2015</arg></template></extension><space/>Chloramphenicol is a<space/><link><target>broad-spectrum antibiotic</target></link><space/>that typically<space/><link><target>bacteriostatic</target><part>stops bacterial growth</part></link><space/>by stopping the making of protein.<extension extension_name='ref' name="AHFS2015"></extension></preline></preblock><preblock><preline>Chloramphenical was discovered in 1947.<extension extension_name='ref'><template><target>cite book</target><arg name="title">Oxford Handbook of Infectious Diseases and Microbiology</arg><arg name="date">2009</arg><arg name="publisher">OUP Oxford</arg><arg name="isbn">9780191039621</arg><arg name="page">56</arg><arg name="url">https://books.google.ca/books?id</arg></template></extension><space/>It is on the<space/><link><target>World Health Organization's List of Essential Medicines</target></link>, the most important medications needed in a basic<space/><link><target>health system</target></link>.<extension extension_name='ref'><template><target>cite web</target><arg name="title">WHO Model List of EssentialMedicines</arg><arg name="url">http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua</arg><arg name="work">World Health Organization</arg><arg name="accessdate">22 April 2014</arg><arg name="date">October 2013</arg></template></extension><space/>It is available as a generic medication.<extension extension_name='ref' name="AHFS2015"></extension><space/>The wholesale cost of an intravenous dose is about 0.40 to 1.90 USD.<extension extension_name='ref' name="ERC2015"><template><target>cite web</target><arg name="title">Chloramphenicol</arg><arg name="url">http://erc.msh.org/dmpguide/resultsdetail.cfm?language</arg><arg name="website">International Drug Price Indicator Guide</arg><arg name="accessdate">26 August 2015</arg></template></extension><space/>In the United States it is very expensive.<extension extension_name='ref' name="Ric2013"><template><target>cite book</target><arg name="last1">Hamilton</arg><arg name="first1">Richard J.</arg><arg name="title">Tarascon pocket pharmacopoeia.</arg><arg name="date">2013</arg><arg name="publisher">Jones & Bartlett Learning</arg><arg name="location">Burlington, MA.</arg><arg name="isbn">9781449673635</arg><arg name="page">89</arg><arg name="edition">14</arg><arg name="url">https://books.google.ca/books?id</arg></template></extension><space/>Global issues with<space/><link><target>bacterial resistance</target></link><space/>maintains interest in its use.<extension extension_name='ref' name="Falagas2008"><template><target>cite journal</target><arg name="author"><space/>Falagas, M. E.; Grammatikos, A. P.; Michalopoulos, A.<space/></arg><arg name="title"><space/>Potential of old-generation antibiotics to address current need for new antibiotics<space/></arg><arg name="journal"><space/>Expert Review of Anti Infective Therapy<space/></arg><arg name="volume"><space/>6<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>593–600<space/></arg><arg name="date">October 2008<space/></arg><arg name="pmid"><space/>18847400<space/></arg><arg name="doi"><space/>10.1586/14787210.6.5.593</arg></template></extension></preline></preblock><paragraph><template><target>TOC limit</target><arg>3</arg></template></paragraph><heading level='2'>Medical uses</heading><paragraph>The original indication of chloramphenicol was in the treatment of<space/><link><target>typhoid</target></link>, but the now almost universal presence of multiple drug-resistant<space/><italics><link><target>Salmonella typhi</target></link></italics><space/>has meant it is seldom used for this indication except when the organism is known to be sensitive. Chloramphenicol may be used as a second-line agent in the treatment of<space/><link><target>tetracycline</target></link>-resistant<space/><link><target>cholera</target></link>.</paragraph><paragraph>Because of its excellent<space/><link><target>blood-brain barrier</target></link><space/>penetration (far superior to any of the<space/><link><target>cephalosporins</target></link>), chloramphenicol remains the first-choice treatment for<space/><link><target>Staphylococcus aureus</target><part>staphylococcal</part></link><space/><link><target>brain abscess</target><trail>es</trail></link>.<template><target>citation needed</target><arg name="date">May 2014</arg></template><space/>It is also useful in the treatment of brain abscesses due to mixed organisms or when the causative organism is not known.</paragraph><paragraph>Chloramphenicol is active against the three main bacterial causes of<space/><link><target>meningitis</target></link>:<space/><italics><link><target>Neisseria meningitidis</target></link></italics>,<space/><italics><link><target>Streptococcus pneumoniae</target></link></italics>, and<space/><italics><link><target>Haemophilus influenzae</target></link></italics>. In the West, chloramphenicol remains the drug of choice in the treatment of meningitis in patients with severe<space/><link><target>penicillin</target></link><space/>or cephalosporin allergy and<space/><link><target>general practitioner</target><trail>s</trail></link><space/>are recommended to carry intravenous chloramphenicol in their bag. In low-income countries, the WHO recommend oily chloramphenicol as first-line to treat meningitis.</paragraph><paragraph>Chloramphenicol has been used in the U.S. in the initial<space/><link><target>empirical treatment</target></link><space/>of children with fever and a<space/><link><target>petechial rash</target></link>, when the<space/><link><target>differential diagnosis</target></link><space/>includes both<space/><italics>Neisseria meningitidis</italics><space/><link><target>septicaemia</target></link><space/>and<space/><link><target>Rocky Mountain spotted fever</target></link>, pending the results of diagnostic investigations.</paragraph><paragraph>Chloramphenicol is also effective against<space/><italics><link><target>Enterococcus faecium</target></link></italics>, which has led to its being considered for treatment of<space/><link><target>vancomycin-resistant enterococcus</target></link>.</paragraph><paragraph>Although unpublished, recent research suggests chloramphenicol could also be applied to frogs to prevent their widespread destruction from fungal infections.<extension extension_name='ref'><template><target>cite news</target><arg name="author"><space/>Griggs, K.<space/></arg><arg name="title"><space/>Frog killer fungus 'breakthrough'<space/></arg><arg name="url"><space/>http://news.bbc.co.uk/2/hi/science/nature/7067613.stm<space/></arg><arg name="date"><space/>2007-10-30<space/></arg><arg name="publisher"><space/>BBC News<space/></arg></template></extension><space/>It has recently been discovered to be a life-saving cure for<space/><link><target>chytridiomycosis</target></link><space/>in<space/><link><target>amphibians</target></link>.<extension extension_name='ref'><template><target>cite web</target><arg name="url"><space/>http://www.nzfrogs.org/site/nzfrog/files/poulter.pdf<space/></arg><arg name="format"><space/>pdf<space/></arg><arg name="title"><space/>Chloramphenicol cures chytridiomycosis<space/></arg><arg name="author"><space/>Poulter, R. T. M.; Busby, J. N.; Bishop, P. J.; Butler, M. I.; Speare, R.<space/></arg><arg name="publisher"><space/>NZ Frogs<space/></arg></template></extension><space/>Chytridiomycosis is a fungal disease, blamed for the extinction of one-third of the 120 frog species lost since 1980.</paragraph><paragraph>The drug should be discontinued upon appearance of<space/><link><target>reticulocytopenia</target></link>,<space/><link><target>leukopenia</target></link>,<space/><link><target>thrombocytopenia</target></link>,<space/><link><target>anemia</target></link>, or any other abnormal blood study findings attributable to chloramphenicol.<extension extension_name='ref' name="Drug Insert from DailyMed"><template><target>cite web</target><arg name="title">Drug Insert from DailyMed</arg><arg name="url">http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid</arg><arg name="accessdate">18 April 2014</arg></template></extension></paragraph><heading level='3'>Spectrum of activity</heading><paragraph>Chloramphenicol has a broad spectrum of activity and has been effective in treating ocular infections caused by a number of bacteria including<space/><italics>Staphylococcus aureus, Streptococcus pneumoniae</italics>, and<space/><italics>Escherichia coli</italics>. It is not effective against<space/><italics>Pseudomonas aeruginosa</italics>. The following susceptibility data represent the<space/><link><target>minimum inhibitory concentration</target></link><space/>for a few medically significant organisms.<extension extension_name='ref'>http://antibiotics.toku-e.com/antimicrobial_507.html</extension></paragraph><list type='bullet'><listitem><italics>Escherichia coli</italics>: 0.015-10,000&amp;nbsp;g/ml</listitem><listitem><italics>Staphylococcus aureus</italics>:<space/><template><target>nowrap</target><arg>0.06 μg/ml - ><space/>128 μg/ml</arg></template></listitem><listitem><italics>Streptococcus pneumoniae</italics>: 2-16&amp;nbsp;g/ml</listitem></list><paragraph>Each of these concentrations is dependent upon the bacterial strain being targeted. Some strains of<space/><italics>E. coli</italics>, for example, show spontaneous emergence of chloramphenicol resistance.<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Carone</arg><arg name="first">BR</arg><arg name="author2">Xu, T<space/></arg><arg name="author3">Murphy, KC<space/></arg><arg name="author4"><space/>Marinus, MG<space/></arg><arg name="title">High incidence of multiple antibiotic resistant cells in cultures of in enterohemorrhagic Escherichia coli O157:H7.</arg><arg name="journal">Mutation research</arg><arg name="date">Jan 2014</arg><arg name="volume">759</arg><arg name="pages">1–8</arg><arg name="pmid">24361397<space/></arg><arg name="doi">10.1016/j.mrfmmm.2013.11.008</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last">Moore</arg><arg name="first">AM</arg><arg name="author2">Patel, S<space/></arg><arg name="author3">Forsberg, KJ<space/></arg><arg name="author4">Wang, B<space/></arg><arg name="author5">Bentley, G<space/></arg><arg name="author6">Razia, Y<space/></arg><arg name="author7">Qin, X<space/></arg><arg name="author8">Tarr, PI<space/></arg><arg name="author9"><space/>Dantas, G<space/></arg><arg name="title">Pediatric fecal microbiota harbor diverse and novel antibiotic resistance genes.</arg><arg name="journal">PLoS ONE</arg><arg name="date">2013</arg><arg name="volume">8</arg><arg name="issue">11</arg><arg name="pages">e78822</arg><arg name="pmid">24236055<space/></arg><arg name="doi">10.1371/journal.pone.0078822<space/></arg><arg name="pmc">3827270</arg></template></extension></paragraph><heading level='3'>Resistance</heading><paragraph>Three mechanisms of<space/><link><target>Antibiotic resistance</target><part>resistance</part></link><space/>to chloramphenicol are known: reduced membrane permeability, mutation of the 50S ribosomal subunit, and elaboration of chloramphenicol acetyltransferase. It is easy to select for reduced membrane permeability to chloramphenicol<space/><italics>in vitro</italics><space/>by serial passage of bacteria, and this is the most common mechanism of low-level chloramphenicol resistance. High-level resistance is conferred by the<space/><italics>cat</italics>-gene; this<space/><link><target>gene</target></link><space/>codes for an<space/><link><target>enzyme</target></link><space/>called<space/><link><target>chloramphenicol acetyltransferase</target></link>, which inactivates chloramphenicol by covalently linking one or two<space/><link><target>acetyl</target></link><space/>groups, derived from acetyl-S-coenzyme A, to the<space/><link><target>hydroxyl</target></link><space/>groups on the chloramphenicol molecule. The acetylation prevents chloramphenicol from binding to the ribosome. Resistance-conferring mutations of the 50S ribosomal subunit are rare.</paragraph><paragraph>Chloramphenicol resistance may be carried on a plasmid that also codes for resistance to other drugs. One example is the<space/><link><target>ACCoT</target></link><space/>plasmid (A=<link><target>ampicillin</target></link>, C=chloramphenicol, Co=<link><target>co-trimoxazole</target></link>, T=<link><target>tetracycline</target></link>), which mediates multiple-drug resistance in typhoid (also called<space/><link><target>R factors</target></link>).</paragraph><paragraph>Currently, some<space/><italics><link><target>Enterococcus faecium</target></link></italics><space/>and<italics><space/><link><target>Pseudomonas aeruginosa</target></link></italics><space/>strains are resistant to chloramphenicol. Some<space/><italics><link><target>Veillonella</target></link></italics><space/>spp. and<space/><italics><link><target>Staphylococcus capitis</target></link></italics><space/>strains have also developed resistance to chloramphenicol to varying degrees.<extension extension_name='ref'><template><target>cite web</target><arg name="title">Chloramphenicol spectrum of bacterial susceptibility and Resistance</arg><arg name="url">http://www.toku-e.com/Upload/Products/PDS/20120618001452.pdf<space/></arg><arg name="accessdate">15 May 2012</arg></template></extension></paragraph><heading level='2'>Adverse effects</heading><heading level='3'>Aplastic anemia</heading><paragraph>The most serious<space/><link><target>adverse drug reaction</target><part>side effect</part></link><space/>of chloramphenicol treatment is<space/><link><target>aplastic anaemia</target></link>.<extension extension_name='ref' name="Rich1950"><template><target>cite journal</target><arg name="author"><space/>Rich, M.; Ritterhoff, R.; Hoffmann, R.<space/></arg><arg name="title"><space/>A fatal case of aplastic anemia following chloramphenicol (chloromycetin) therapy<space/></arg><arg name="journal"><space/>Annals of Internal Medicine<space/></arg><arg name="volume"><space/>33<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>1459–1467<space/></arg><arg name="date">December 1950<space/></arg><arg name="pmid"><space/>14790529<space/></arg><arg name="doi"><space/>10.7326/0003-4819-33-6-1459<space/></arg></template></extension><space/>This effect is rare and is generally fatal. No treatment is available and no way exists to predict who may or may not get this side effect. The effect usually occurs weeks or months after treatment has been stopped, and a genetic predisposition may be involved.<extension extension_name='ref'><template><target>cite journal</target><arg name="doi"><space/>10.1056/NEJM196907032810102<space/></arg><arg name="author"><space/>Nagao, T.; Mauer, A.<space/></arg><arg name="title"><space/>Concordance for drug-induced aplastic anemia in identical twins<space/></arg><arg name="journal"><space/>New England Journal of Medicine<space/></arg><arg name="volume"><space/>281<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>7–11<space/></arg><arg name="date">July 1969<space/></arg><arg name="pmid"><space/>5785754<space/></arg></template></extension><space/>It is not known whether monitoring the<space/><link><target>blood count</target><trail>s</trail></link><space/>of patients can prevent the development of aplastic anaemia, but patients are recommended to have a baseline blood count with a repeat blood count every few days while on treatment.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Hammett-Stabler, C.; Johns, T.<space/></arg><arg name="title"><space/>Laboratory guidelines for monitoring of antimicrobial drugs<space/></arg><arg name="journal"><space/>Clinical Chemistry<space/></arg><arg name="volume"><space/>44</arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>1129–1140<space/></arg><arg name="date">May 1988<space/></arg><arg name="pmid"><space/>9590397<space/></arg></template></extension><space/>Chloramphenicol should be discontinued if the complete blood count drops below 2.5 x 10 cells/l. The highest risk is with oral chloramphenicol<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Holt, R.<space/></arg><arg name="journal"><space/>Lancet<space/></arg><arg name="title"><space/>The bacterial degradation of chloramphenicol<space/></arg><arg name="year"><space/>1967<space/></arg><arg name="volume"><space/>289<space/></arg><arg name="pages"><space/>1259–1260<space/></arg><arg name="doi"><space/>10.1016/S0140-6736(67)92720-1<space/></arg><arg name="pmid"><space/>4165044<space/></arg><arg name="issue"><space/>7502<space/></arg></template></extension><space/>(affecting 1 in 24,00040,000)<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Wallerstein, R.; Condit, P.; Kasper, C.; Brown, J.; Morrison, F.<space/></arg><arg name="title"><space/>Statewide study of chloramphenicol therapy and fatal aplastic anemia<space/></arg><arg name="journal"><space/>JAMA<space/></arg><arg name="volume"><space/>208<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>2045–2050<space/></arg><arg name="date">June 1969<space/></arg><arg name="pmid"><space/>5818983<space/></arg><arg name="doi"><space/>10.1001/jama.208.11.2045<space/></arg></template></extension><space/>and the lowest risk occurs with eye drops (affecting less than one in 224,716 prescriptions).<extension extension_name='ref' name="Lancaster1998"></extension></paragraph><paragraph><link><target>Thiamphenicol</target></link>, a related compound with a similar spectrum of activity, is available in Italy and China for human use, and has never been associated with aplastic anaemia<space/><template><target>Citation needed</target><arg name="date">November 2009</arg></template>. Thiamphenicol is available in the U.S. and Europe as a<space/><link><target>veterinary</target></link><space/>antibiotic, but is not approved for use in humans.</paragraph><heading level='3'>Bone marrow suppression</heading><paragraph>Chloramphenicol may cause<space/><link><target>bone marrow suppression</target></link><space/>during treatment; this is a direct toxic effect of the drug on human<space/><link><target>mitochondria</target></link>.<extension extension_name='ref' name="pmid2486534"><template><target>cite journal</target><arg name="author">Yunis AA<space/></arg><arg name="title">Chloramphenicol toxicity: 25 years of research<space/></arg><arg name="journal">Am. J. Med.<space/></arg><arg name="volume">87<space/></arg><arg name="issue">3N<space/></arg><arg name="pages">44N–48N<space/></arg><arg name="date">September 1989<space/></arg><arg name="pmid">2486534<space/></arg></template></extension><space/>This effect manifests first as a fall in<space/><link><target>hemoglobin</target></link><space/>levels, which occurs quite predictably once a cumulative dose of 20 g has been given. The anaemia is fully reversible once the drug is stopped and does not predict future development of aplastic anaemia. Studies in mice have suggested existing marrow damage may compound any marrow damage resulting from the toxic effects of chloramphenicol.<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Morley</arg><arg name="first">Alec</arg><arg name="author2">Trainor, Kevin<space/></arg><arg name="author3">Remes, Judith<space/></arg><arg name="title">Residual Marrow Damage: Possible Explanation for Idiosyncrasy to Chloramphenicol</arg><arg name="journal">British Journal of Haematology</arg><arg name="date">1 April 1976</arg><arg name="volume">32</arg><arg name="issue">4</arg><arg name="pages">525–532</arg><arg name="doi">10.1111/j.1365-2141.1976.tb00955.x</arg></template></extension></paragraph><heading level='3'>Leukemia</heading><paragraph>Leukemia, a cancer of the blood or bone marrow, is characterized by an abnormal increase of immature white blood cells. The risk of childhood<space/><link><target>leukemia</target></link><space/>is increased, as demonstrated in a Chinese<space/><link><target>case-controlled study</target></link>,<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Shu, X.; Gao, Y.; Linet, M.; Brinton, L.; Gao, R.; Jin, F.; Fraumeni, J.<space/></arg><arg name="title"><space/>Chloramphenicol use and childhood leukaemia in Shanghai<space/></arg><arg name="journal"><space/>Lancet<space/></arg><arg name="volume"><space/>2<space/></arg><arg name="issue"><space/>8565<space/></arg><arg name="pages"><space/>934–937<space/></arg><arg name="date">October 1987<space/></arg><arg name="pmid"><space/>2889862<space/></arg><arg name="doi"><space/>10.1016/S0140-6736(87)91420-6<space/></arg></template></extension><space/>and the risk increases with length of treatment.</paragraph><heading level='3'>Gray baby syndrome</heading><paragraph>Intravenous chloramphenicol use has been associated with the so-called<space/><link><target>gray baby syndrome</target></link>.<extension extension_name='ref' name="McIntyre_2004"><template><target>cite journal</target><arg name="author"><space/>McIntyre, J.; Choonara, I.<space/></arg><arg name="title"><space/>Drug toxicity in the neonate<space/></arg><arg name="journal"><space/>Biology of the Neonate<space/></arg><arg name="volume"><space/>86<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>218–221<space/></arg><arg name="year"><space/>2004<space/></arg><arg name="pmid"><space/>15249753<space/></arg><arg name="doi"><space/>10.1159/000079656<space/></arg></template></extension>This phenomenon occurs in newborn infants because they do not yet have fully functional liver enzymes (i.e. UDP-glucuronyl transferase), so chloramphenicol remains unmetabolized in the body.<extension extension_name='ref' name="Pieiro-Carrero_2004"><template><target>cite journal</target><arg name="author"><space/>Piñeiro-Carrero, V.; Piñeiro, E.<space/></arg><arg name="title"><space/>Liver<space/></arg><arg name="journal"><space/>Pediatrics<space/></arg><arg name="volume"><space/>113<space/></arg><arg name="issue"><space/>4 Supplement<space/></arg><arg name="pages"><space/>1097–1106<space/></arg><arg name="year"><space/>2004<space/></arg><arg name="pmid"><space/>15060205<space/></arg><arg name="url"><space/>http://pediatrics.aappublications.org/content/113/Supplement_3/1097.full.pdf<space/></arg><arg name="format"><space/>pdf<space/></arg></template></extension>This causes several adverse effects, including<space/><link><target>hypotension</target></link><space/>and<space/><link><target>cyanosis</target></link>. The condition can be prevented by using the drug at the recommended doses, and monitoring blood levels.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Feder, H.<space/></arg><arg name="title"><space/>Chloramphenicol: what we have learned in the last decade<space/></arg><arg name="journal"><space/>Southern Medical Journal<space/></arg><arg name="volume"><space/>79<space/></arg><arg name="issue"><space/>9<space/></arg><arg name="pages"><space/>1129–1134<space/></arg><arg name="year"><space/>1986<space/></arg><arg name="pmid"><space/>3529436<space/></arg><arg name="doi"><space/>10.1097/00007611-198609000-00022<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Mulhall, A.; de Louvois J.; Hurley, R.<space/></arg><arg name="title"><space/>Chloramphenicol toxicity in neonates: its incidence and prevention<space/></arg><arg name="journal"><space/>British Medical Journal (Clinical Research Edition)<space/></arg><arg name="volume"><space/>287<space/></arg><arg name="issue"><space/>6403<space/></arg><arg name="pages"><space/>1424–1427<space/></arg><arg name="year"><space/>1983<space/></arg><arg name="pmid"><space/>6416440<space/></arg><arg name="pmc"><space/>1549666<space/></arg><arg name="doi"><space/>10.1136/bmj.287.6403.1424<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Forster, J.; Hufschmidt, C.; Niederhoff, H.; Künzer, W.<space/></arg><arg name="title"><space/>[Need for the determination of chloramphenicol levels in the treatment of bacterial-purulent meningitis with chloramphenicol succinate in infants and small children]<space/></arg><arg name="language"><space/>German<space/></arg><arg name="journal"><space/>Monatsschrift Kinderheilkunde<space/></arg><arg name="volume"><space/>133<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>209–213<space/></arg><arg name="year"><space/>1985<space/></arg><arg name="pmid"><space/>4000136<space/></arg></template></extension></paragraph><heading level='3'>Hypersensitivity reactions</heading><paragraph>Fever, macular and vesicular rashes, angioedema, urticaria, and anaphylaxis may occur. Herxheimers reactions have occurred during therapy for typhoid fever.<extension extension_name='ref' name="Drug Insert from DailyMed"></extension></paragraph><heading level='3'>Neurotoxic reactions</heading><paragraph>Headache, mild depression, mental confusion, and delirium have been described in patients receiving chloramphenicol. Optic and peripheral neuritis have been reported, usually following long-term therapy. If this occurs, the drug should be promptly withdrawn.<extension extension_name='ref' name="Drug Insert from DailyMed"></extension></paragraph><heading level='2'>Pharmacokinetics</heading><paragraph>Chloramphenicol is extremely lipid-soluble; it remains relatively<space/><link><target>plasma protein binding</target><part>unbound to protein</part></link><space/>and is a small molecule. It has a large apparent<space/><link><target>volume of distribution</target></link><space/>and penetrates effectively into all tissues of the body, including the brain. Distribution is not uniform, with highest concentrations found in the liver and kidney, with lowest in the brain and cerebrospinal fluid.<extension extension_name='ref' name="Drug Insert from DailyMed"></extension><space/>The concentration achieved in brain and<space/><link><target>cerebrospinal fluid</target></link><space/>is around 30 to 50% of the overall average body concentration, even when the meninges are not inflamed; this increases to as high as 89% when the meninges are inflamed.</paragraph><paragraph>Chloramphenicol increases the absorption of<space/><link><target>Human iron metabolism</target><part>iron</part></link>.<extension extension_name='ref'><template><target>cite encyclopedia</target><arg name="encyclopedia"><space/>Pill Book, The<space/></arg><arg name="title"><space/>Iron Supplements<space/></arg><arg name="pages"><space/>593–596<space/></arg><arg name="editor"><space/>Harold M. Silverman, Pharm.D. (editor-in-chief)<space/></arg><arg name="publisher"><space/>Bantam Dell<space/></arg><arg name="location"><space/>New York<space/></arg><arg name="edition"><space/>12th revised<space/></arg><arg name="year"><space/>2006<space/></arg><arg name="isbn"><space/>978-0-553-58892-7<space/></arg></template></extension></paragraph><heading level='3'>Use in special populations</heading><paragraph>Chloramphenicol is metabolized by the liver to chloramphenicol<space/><link><target>glucuronic acid</target><part>glucuronate</part></link><space/>(which is inactive). In liver impairment, the dose of chloramphenicol must therefore be reduced. No standard dose reduction exists for chloramphenicol in liver impairment, and the dose should be adjusted according to measured plasma concentrations.</paragraph><paragraph>The majority of the chloramphenicol dose is excreted by the kidneys as the inactive metabolite, chloramphenicol glucuronate. Only a tiny fraction of the chloramphenicol is excreted by the kidneys unchanged. Plasma levels should be monitored in patients with renal impairment, but this is not mandatory. Chloramphenicol succinate ester (an intravenous<space/><link><target>prodrug</target></link><space/>form) is readily excreted unchanged by the kidneys, more so than chloramphenicol base, and this is the major reason why levels of chloramphenicol in the blood are much lower when given intravenously than orally.<template><target>Citation needed</target><arg name="date">November 2009</arg></template></paragraph><paragraph>Chloramphenicol passes into<space/><link><target>breast milk</target></link>, so should therefore be avoided during breast feeding, if possible.<extension extension_name='ref' name="kidsgrowth"><link type='external' href='http://www.kidsgrowth.org/resources/articledetail.cfm?id=471'>kidsgrowth.org --&gt; Drugs and Other Substances in Breast Milk</link><space/>Retrieved on June 19, 2009</extension></paragraph><heading level='3'>Dose monitoring</heading><paragraph><link><target>Blood plasma</target><part>Plasma</part></link><space/>levels of chloramphenicol must be monitored in neonates and patients with abnormal liver function. Plasma levels should be monitored in all children under the age of four, the elderly, and patients with renal failure.Because efficacy and toxicity of chloramphenicol are associated with a maximum serum concentration, peak levels (one hour after the intravenous dose is given) should be 10-20&amp;nbsp;g/ml with toxicity<space/><template><target>nowrap</target><arg>><space/>40 µg/ml</arg></template>; trough levels (taken immediately before a dose) should be 5-10&amp;nbsp;g/ml.<extension extension_name='ref' name="Laboratory guidelines for monitoring of antimicrobial drugs"><template><target>cite journal</target><arg name="last">Hammett-Stabler</arg><arg name="first">C</arg><arg name="author2">Johns, T.</arg><arg name="title">Laboratory guidelines for monitoring of antimicrobial drugs</arg><arg name="journal">Clinical Chemistry</arg><arg name="date">May 1988</arg><arg name="volume">44</arg><arg name="issue">5</arg><arg name="pages">1129–1140</arg><arg name="pmid">9590397</arg><arg name="accessdate">17 April 2014</arg></template></extension><extension extension_name='ref' name="Lexicomp Online Database"><template><target>cite web</target><arg name="title">Chloramphenicol (Lexi-Drugs)</arg><arg name="url">http://online.lexi.com.proxy1.lib.tju.edu/lco/action/doc/retrieve/docid/patch_f/6582</arg><arg name="work">Lexi-Comp Online</arg><arg name="accessdate">18 April 2014</arg></template></extension></paragraph><heading level='3'>Drug interactions</heading><paragraph>Administration of chloramphenicol concomitantly with bone marrow depressant drugs is contraindicated, although concerns over aplastic anaemia associated with ocular chloramphenicol have largely been discounted.<extension extension_name='ref'><link type='external' href='http://www.rpsgb.org.uk/pdfs/otcchlorampheneyedropsguid.pdf'></link><space/>June 2005. Royal Pharmaceutical Society of Great Britain (RPSGB)</extension></paragraph><paragraph>Chloramphenicol is a potent inhibitor of the<space/><link><target>cytochrome P450</target></link><space/><link><target>isoforms</target></link><space/><link><target>CYP2C19</target></link><space/>and<space/><link><target>CYP3A4</target></link><space/>in the liver.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Park, J. Y.; Kim, K. A.; Kim, S. L.<space/></arg><arg name="title"><space/>Chloramphenicol Is a Potent Inhibitor of Cytochrome P450 Isoforms CYP2C19 and CYP3A4 in Human Liver Microsomes<space/></arg><arg name="journal"><space/>Antimicrobial Agents and Chemotherapy<space/></arg><arg name="volume"><space/>47<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>3464–3469<space/></arg><arg name="date">November 2003<space/></arg><arg name="pmid"><space/>14576103<space/></arg><arg name="pmc"><space/>253795<space/></arg><arg name="doi"><space/>10.1128/AAC.47.11.3464-3469.2003<space/></arg><arg name="url"><space/></arg></template></extension><space/>Inhibition of CYP2C19 causes decreased metabolism and therefore increased levels of, for example,<space/><link><target>antidepressants</target></link>,<space/><link><target>antiepileptics</target></link>,<space/><link><target>proton pump inhibitors</target></link>, and<space/><link><target>anticoagulant</target><trail>s</trail></link><space/>if they are given concomitantly. Inhibition of CYP3A4 causes increased levels of, for example,<space/><link><target>calcium channel blockers</target></link>,<space/><link><target>immunosuppressants</target></link>,<space/><link><target>chemotherapeutic drugs</target></link>,<space/><link><target>benzodiazepines</target></link>, azole<space/><link><target>antifungals</target></link>,<space/><link><target>tricyclic antidepressant</target><trail>s</trail></link>,<space/><link><target>macrolide</target></link><space/>antibiotics,<space/><link><target>Selective serotonin reuptake inhibitor</target><part>SSRI</part><trail>s</trail></link>,<space/><link><target>statins</target></link>,<space/><link><target>Antiarrhythmic agent</target><part>cardiac antiarrhythmics</part></link>,<space/><link><target>Antiviral drug</target><part>antivirals</part></link>,<space/><link><target>anticoagulant</target><trail>s</trail></link>, and<space/><link><target>PDE5 inhibitor</target><trail>s</trail></link>.<extension extension_name='ref' name="Drug Insert from DailyMed"></extension><extension extension_name='ref' name="FASS"><template><target>cite web</target><arg name="url"><space/>http://www.fass.se/LIF/produktfakta/fakta_lakare_artikel.jsp?articleID</arg><arg name="title"><space/>Facts for prescribers (Fakta för förskrivare)<space/></arg><arg name="language"><space/>swedish<space/></arg><arg name="publisher"><space/>FASS - Swedish National Drug Formulary<space/></arg></template></extension></paragraph><heading level='3'>Drug antagonistic</heading><paragraph>Bacteriostatic Chloramphenicol is antagonistic with bactericidal<space/><link><target>Cephalosporin</target></link><space/>and should be avoided in the treatment of infections.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.researchgate.net/publication/19960295_Antagonistic_effect_of_chloramphenicol_in_combination_with_cefotaxime_or_ceftriaxone<space/></arg><arg name="title">Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone<space/></arg><arg name="accessdate">August 25, 2014</arg></template></extension></paragraph><heading level='2'>Mechanism of action</heading><paragraph>Chloramphenicol is a<space/><link><target>Bacteriostatic agent</target><part>bacteriostatic</part></link><space/>by<space/><link><target>protein synthesis inhibitor</target><part>inhibiting protein synthesis</part></link>. It prevents<space/><link><target>protein synthesis</target><part>protein chain elongation</part></link><space/>by inhibiting the<space/><link><target>peptidyl transferase</target></link><space/>activity of the bacterial<space/><link><target>ribosome</target></link>. It specifically binds to A2451 and A2452 residues<extension extension_name='ref'><template><target>cite journal</target><arg name="title"><space/>Mycobacterial toxin MazF-mt6 inhibits translation through cleavage of 23S rRNA at the ribosomal A site<space/></arg><arg name="date"><space/>May 2013<space/></arg><arg name="journal"><space/>Proceedings of the National Academy of Sciences of the United States of America<space/></arg><arg name="author"><space/>Schifano JM, Edifor R, Sharp JD<space/></arg><arg name="pmid"><space/>23650345<space/></arg><arg name="pmc">3666664<space/></arg><arg name="doi">10.1073/pnas.1222031110<space/></arg><arg name="volume">110<space/></arg><arg name="pages">8501–6</arg><arg name="display-authors">etal</arg></template></extension><space/>in the<space/><link><target>23S ribosomal RNA</target><part>23S rRNA</part></link><space/>of the 50S ribosomal subunit, preventing peptide bond formation.<extension extension_name='ref'><template><target>cite web</target><arg name="url"><space/>http://merck.com/mmpe/sec14/ch170/ch170d.html<space/></arg><arg name="title"><space/>Chloramphenicol<space/></arg><arg name="work"><space/>The Merck Manual<space/></arg><arg name="publisher"><space/>Merck<space/></arg></template></extension><space/>While chloramphenicol and the<space/><link><target>macrolide</target></link><space/>class of antibiotics both interact with ribosomes, chloramphenicol is not a macrolide. It directly interferes with substrate binding, whereas macrolides sterically block the progression of the growing peptide.<extension extension_name='ref'><template><target>cite journal</target><arg name="url"><space/>http://www.jbc.org/content/238/7/2498.full.pdf<space/></arg><arg name="format"><space/>pdf<space/></arg><arg name="title"><space/>Studies on the Mechanism of Action of Chloramphenicol - The Conformation of Chloramphenicol in Solution<space/></arg><arg name="date"><space/>July 1963<space/></arg><arg name="journal"><space/>The Journal of Biological Chemistry<space/></arg><arg name="volume"><space/>238<space/></arg><arg name="issue"><space/>7<space/></arg><arg name="author"><space/>Jardetzky, O.<space/></arg><arg name="pmid"><space/>13957484<space/></arg><arg name="pages"><space/>2498–2508<space/></arg></template></extension><extension extension_name='ref'><template><target>Cite journal</target><arg name="last1"><space/>Wolfe<space/></arg><arg name="first1"><space/>A. D. 
</arg><arg name="last2"><space/>Hahn<space/></arg><arg name="first2"><space/>F. E. 
</arg><arg name="title"><space/>Mode of Action of Chloramphenicol. IX. Effects of Chloramphenicol Upon a Ribosomal Amino Acid Polymerization System and Its Binding to Bacterial Ribosome 
</arg><arg name="journal"><space/>Biochimica et Biophysica Acta 
</arg><arg name="volume"><space/>95 
</arg><arg name="pages"><space/>146–155 
</arg><arg name="year"><space/>1965 
</arg><arg name="pmid"><space/>14289020
<space/></arg><arg name="doi">10.1016/0005-2787(65)90219-4
</arg></template></extension><extension extension_name='ref'><template><target>Cite journal</target><arg name="last1"><space/>Hahn<space/></arg><arg name="first1"><space/>F. E. 
</arg><arg name="last2"><space/>Wisseman<space/></arg><arg name="first2"><space/>C. L. Jr.
</arg><arg name="last3"><space/>Hopps<space/></arg><arg name="first3"><space/>H. E. 
</arg><arg name="title"><space/>Mode of Action of Chloramphenicol III. : Action of Chloramphenicol on Bacterial Energy Metabolism 
</arg><arg name="journal"><space/>Journal of Bacteriology 
</arg><arg name="volume"><space/>69 
</arg><arg name="issue"><space/>2 
</arg><arg name="pages"><space/>215–223 
</arg><arg name="year"><space/>1955 
</arg><arg name="pmid"><space/>14353832 
</arg><arg name="pmc"><space/>357505
</arg></template></extension></paragraph><heading level='2'>History</heading><paragraph>Chloramphenicol was originally derived from the<space/><link><target>bacterium</target></link><space/><italics><link><target>Streptomyces venezuelae</target></link></italics>, isolated by<space/><link><target>David Gottlieb</target></link>, and introduced into clinical practice in 1949, under the trade name Chloromycetin. It was the first antibiotic to be manufactured synthetically on a large scale.</paragraph><paragraph>The topical formulation of chloramphenicol was commonly used as eye drops as first-line treatment of conjunctivitis. The first fatality from eye drops was reported in 1955.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>R.L. Rosenthal, A. Blackman<space/></arg><arg name="title"><space/>Bone-marrow hypoplasia following use of chloramphenicol eye drops<space/></arg><arg name="journal"><space/>JAMA<space/></arg><arg name="volume"><space/>191<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>136–137<space/></arg><arg name="date">1965<space/></arg><arg name="doi">10.1001/jama.1965.03080020064025</arg></template></extension></paragraph><paragraph>In 2007, the accumulation of reports associating aplastic anemia and blood dyscrasia with chloramphenicol eye drops lead to the classification of probable according to World Health Organization criteria, based on the known published case reports and the spontaneous reports submitted to the National Registry of Drug-Induced Ocular Side Effects.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Fraunfelder, F.; Fraunfelder, F<space/></arg><arg name="title"><space/>Restricting Topical Ocular Chloramphenicol Eye Drop Use in the United States. Did We Overreact?<space/></arg><arg name="journal"><space/>American Journal of Ophtalmology<space/></arg><arg name="volume"><space/>156</arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>420–422<space/></arg><arg name="date">September 2013<space/></arg><arg name="pmid"><space/>23953152<space/></arg><arg name="doi"><space/>10.1016/j.ajo.2013.05.004</arg></template></extension></paragraph><heading level='2'>Society and culture</heading><heading level='3'>Cost</heading><paragraph>In many areas of the world an intravenous dose is about 0.40 to 1.90 USD.<extension extension_name='ref' name="ERC2015"></extension><space/>In the United States it is very expensive.<extension extension_name='ref' name="Ric2013"></extension></paragraph><heading level='3'>Names</heading><paragraph>Chloramphenicol is available as a generic worldwide under many brandnames<extension extension_name='ref'>Drugs.com<space/><link type='external' href='http://www.drugs.com/international/chloramphenicol.html'>drugs.com international listings for chloramphenicol</link><space/>Page accessed July 9, 2015</extension><space/>and also under various generic names in eastern Europe and Russia, including chlornitromycin, levomycetin, and chloromycetin; the racemate is known as synthomycetin.<extension extension_name='ref' name="levomyc-free-sovdict"><template><target>cite book</target><arg name="title">The Great Soviet Encyclopedia, 3rd Edition, 1970-1979</arg><arg name="publisher">The Gale Group, Inc.</arg><arg name="edition">3</arg><arg name="url">http://encyclopedia2.thefreedictionary.com/Levomycetin</arg><arg name="accessdate">10 July 2015</arg></template></extension></paragraph><heading level='3'>Formulations</heading><paragraph><link><target>File:Sample of Chloramphenicol.jpg</target><part>thumb</part><part>Pure chloramphenicol</part></link>Chloramphenicol is available as a capsules or as a liquid . In some countries, it is sold as chloramphenicol<space/><link><target>palmitate</target></link><space/><link><target>ester</target></link><space/>(CPE). CPE is inactive, and is<space/><link><target>hydrolysis</target><part>hydrolysed</part></link><space/>to active chloramphenicol in the<space/><link><target>small intestine</target></link>. No difference in<space/><link><target>bioavailability</target></link><space/>is noted between chloramphenicol and CPE.</paragraph><paragraph>Manufacture of oral chloramphenicol in the U.S. stopped in 1991, because the vast majority of chloramphenicol-associated cases of aplastic anaemia are associated with the oral preparation. No oral formulation of chloramphenicol is now available in the U.S.</paragraph><paragraph>In molecular biology, chloramphenicol is prepared in ethanol.</paragraph><heading level='4'>Intravenous</heading><paragraph>The<space/><link><target>intravenous</target></link><space/>(IV) preparation of chloramphenicol is the succinate ester, because pure chloramphenicol does not dissolve in water. This creates a problem: Chloramphenicol succinate ester is an inactive<space/><link><target>prodrug</target></link><space/>and must first be hydrolysed to chloramphenicol; however, the hydrolysis process is often incomplete, and 30% of the dose is lost and removed in the urine. Serum concentrations of IV chloramphenicol are only 70% of those achieved when chloramphenicol is given orally.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Glazko, A. J.; Dill, W. A.; Kinkel, A. W.<space/></arg><arg name="title"><space/>Absorption and excretion of parenteral doses of chloramphenicol sodium succinate in comparison with per oral doses of chloramphenicol (abstract)<space/></arg><arg name="journal"><space/>Clinical Pharmacological Therapy<space/></arg><arg name="year"><space/>1977<space/></arg><arg name="volume"><space/>21<space/></arg><arg name="pages"><space/>104<space/></arg></template></extension><space/>For this reason, the dose needs to be increased to 75&amp;nbsp;mg/kg/day when administered IV to achieve levels equivalent to the oral dose.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Bhutta, Z.; Niazi, S.; Suria, A.<space/></arg><arg name="title"><space/>Chloramphenicol Clearance in Typhoid Fever: Implications for Therapy<space/></arg><arg name="journal"><space/>Indian Journal of Pediatry<space/></arg><arg name="volume"><space/>59<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>213–219<space/></arg><arg name="date">March–April 1992<space/></arg><arg name="pmid"><space/>1398851<space/></arg><arg name="doi"><space/>10.1007/BF02759987<space/></arg></template></extension></paragraph><heading level='4'>Oily</heading><paragraph>Oily chloramphenicol (or chloramphenicol oil suspension) is a long-acting preparation of chloramphenicol first introduced by Roussel in 1954; marketed as Tifomycine, it was originally used as a treatment for<space/><link><target>typhoid</target></link>. Roussel stopped production of oily chloramphenicol in 1995; the<space/><link><target>International Dispensary Association</target></link><space/>has manufactured it since 1998, first in<space/><link><target>Malta</target></link><space/>and then in<space/><link><target>India</target></link><space/>from December 2004.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Lewis, R. F.; Dorlencourt, F.; Pinel, J.<space/></arg><arg name="title"><space/>Long-acting oily Chloramphenicol for Meningococcal Meningitis<space/></arg><arg name="journal"><space/>Lancet<space/></arg><arg name="volume"><space/>352<space/></arg><arg name="issue"><space/>9130<space/></arg><arg name="page"><space/>823<space/></arg><arg name="year"><space/>1998<space/></arg><arg name="pmid"><space/>9737323<space/></arg><arg name="doi"><space/>10.1016/S0140-6736(05)60723-4<space/></arg></template></extension></paragraph><paragraph>Oily chloramphenicol is recommended by the World Health Organization as the first-line treatment of meningitis in low-income countries, and appears on the<space/><link><target>WHO Model List of Essential Medicines</target><part>WHO essential drugs list</part></link>. It was first used to treat meningitis in 1975<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Rey, M.; Ouedraogo, L.; Saliou, P.; Perino, L.<space/></arg><arg name="title"><space/>Traitement minute de la méningite cérébrospinale épidémique par injection intramusculaire unique de chloramphénicol (suspension huileuse)<space/></arg><arg name="journal"><space/>Médecine et Maladies Infectieuses<space/></arg><arg name="language"><space/>french<space/></arg><arg name="year"><space/>1976<space/></arg><arg name="volume"><space/>6<space/></arg><arg name="pages"><space/>120–124<space/></arg><arg name="doi"><space/>10.1016/S0399-077X(76)80134-5<space/></arg><arg name="issue"><space/>4<space/></arg></template></extension><space/>and numerous studies since have demonstrated its efficacy.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Wali, S.; Macfarlane, J.; Weir, W.; Cleland, P.; Ball, P.; Hassan-King, M.; Whittle, H.; Greenwood, B.<space/></arg><arg name="title"><space/>Single injection treatment of meningococcal meningitis. 2. Long-acting chloramphenicol<space/></arg><arg name="journal"><space/>Transactions of the Royal Society for Tropical Medicine and Hygiene<space/></arg><arg name="volume"><space/>73<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>698–702<space/></arg><arg name="year"><space/>1979<space/></arg><arg name="pmid"><space/>538813<space/></arg><arg name="doi"><space/>10.1016/0035-9203(79)90024-5<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Puddicombe, J.; Wali, S.; Greenwood, B.<space/></arg><arg name="title"><space/>A field trial of a single intramuscular injection of long-acting chloramphenicol in the treatment of meningococcal meningitis<space/></arg><arg name="journal"><space/>Transactions of the Royal Society for Tropical Medicine and Hygiene<space/></arg><arg name="volume"><space/>78<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>399–403<space/></arg><arg name="year"><space/>1984<space/></arg><arg name="pmid"><space/>6464136<space/></arg><arg name="doi"><space/>10.1016/0035-9203(84)90132-9<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Pécoulm B.; Varaine, F.; Keita, M.; Soga, G.; Djibo, A.; Soula, G.; Abdou, A.; Etienne, J.; Rey, M.<space/></arg><arg name="title"><space/>Long-acting chloramphenicol versus intravenous ampicillin for treatment of bacterial meningitis<space/></arg><arg name="journal"><space/>Lancet<space/></arg><arg name="volume"><space/>338<space/></arg><arg name="issue"><space/>8771<space/></arg><arg name="pages"><space/>862–866<space/></arg><arg name="date">October 1991<space/></arg><arg name="pmid"><space/>1681224<space/></arg><arg name="doi"><space/>10.1016/0140-6736(91)91511-R<space/></arg></template></extension><space/>It is the cheapest treatment available for meningitis (US$5 per treatment course, compared to US$30 for<space/><link><target>ampicillin</target></link><space/>and US$15 for five days of<space/><link><target>ceftriaxone</target></link>). It has the great advantage of requiring only a single injection, whereas ceftriaxone is traditionally given daily for five days. This recommendation may yet change, now that a single dose of ceftriaxone (cost US$3) has been shown to be equivalent to one dose of oily chloramphenicol.<extension extension_name='ref'><template><target>cite journal</target><arg name="title"><space/>Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study<space/></arg><arg name="journal"><space/>Lancet<space/></arg><arg name="author"><space/>Nathan, N.; Borel, T.; Djibo, A.<space/></arg><arg name="year"><space/>2005<space/></arg><arg name="volume"><space/>366<space/></arg><arg name="issue"><space/>9482<space/></arg><arg name="pages"><space/>308–313<space/></arg><arg name="pmid"><space/>16039333<space/></arg><arg name="doi">10.1016/S0140-6736(05)66792-X<space/></arg></template></extension></paragraph><heading level='4'>Eye drops</heading><paragraph>Chloramphenicol is still widely used in topical preparations (<link><target>ointment</target><trail>s</trail></link><space/>and<space/><link><target>eye drop</target><trail>s</trail></link>) for the treatment of bacterial conjunctivitis. Isolated case reports of<space/><link><target>aplastic anaemia</target></link><space/>following use of chloramphenicol eyedrops exist, but the risk is estimated to be less than one in 224,716 prescriptions.<extension extension_name='ref' name="Lancaster1998"><template><target>cite journal</target><arg name="author"><space/>Lancaster, T.; Stewart, A. M.; Jick, H.<space/></arg><arg name="title"><space/>Risk of serious haematological toxicity with use of chloramphenicol eye drops in a British general practice database<space/></arg><arg name="journal"><space/>British Medical Journal<space/></arg><arg name="year"><space/>1998<space/></arg><arg name="volume"><space/>316<space/></arg><arg name="pages"><space/>667<space/></arg><arg name="pmid"><space/>9522792<space/></arg><arg name="url"><space/>http://bmj.bmjjournals.com/cgi/content/full/316/7132/667<space/></arg><arg name="issue"><space/>7132<space/></arg><arg name="pmc"><space/>28473<space/></arg><arg name="doi"><space/>10.1136/bmj.316.7132.667<space/></arg></template></extension><space/>In<space/><link><target>Mexico</target></link>, this is the treatment used<space/><link><target>prophylactic</target><trail>ally</trail></link><space/>in newborns.</paragraph><heading level='2'>Veterinary uses</heading><paragraph>Although its use in veterinary medicine is highly restricted, chloramphenicol still has some important veterinary uses.<extension extension_name='ref'><template><target>cite web</target><arg name="title">Chloramphenicol and Congeners</arg><arg name="url">http://www.merckmanuals.com/vet/pharmacology/antibacterial_agents/chloramphenicol_and_congeners.html</arg><arg name="publisher">Merck Manuals</arg><arg name="accessdate">31 October 2014</arg></template></extension><space/>It is currently considered the most useful treatment of chlamydial disease in koalas.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Govendir</arg><arg name="first1">M</arg><arg name="title">Plasma concentrations of chloramphenicol after subcutaneous administration to koalas (Phascolarctos cinereus) with chlamydiosis</arg><arg name="journal">Journal of Veterinary Pharmacology and Therapeutics</arg><arg name="volume">35</arg><arg name="date">16 May 2011</arg><arg name="pages">147–154</arg><arg name="doi">10.1111/j.1365-2885.2011.01307.x</arg></template></extension><extension extension_name='ref' name="Griffith"><template><target>cite journal</target><arg name="last1">Griffith</arg><arg name="first1">J.</arg><arg name="title">Diagnosis, treatment and outcomes for koala chlamydiosis at a rehabilitation facility (1995–2005)</arg><arg name="journal">Australian Veterinary Journal</arg><arg name="date">2012</arg><arg name="volume">90</arg><arg name="issue">90</arg><arg name="pages">457–463</arg><arg name="doi">10.1111/j.1751-0813.2012.00963.x</arg><arg name="pmid">23106328</arg></template></extension><space/>The pharmacokinetics of chloramphenicol have been investigated in koalas.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Black</arg><arg name="first1">Lisa</arg><arg name="journal">Journal of Veterinary Pharmacology and Therapeutics</arg><arg name="volume">36</arg><arg name="pages">478–485</arg><arg name="doi">10.1111/jvp.12024</arg><arg name="title">Pharmacokinetics of chloramphenicol following administration of intravenous and subcutaneous chloramphenicol sodium succinate, and subcutaneous chloramphenicol, to koalas ( Phascolarctos cinereus )</arg></template></extension></paragraph><heading level='2'>References</heading><paragraph><template><target>reflist</target><arg>32em</arg></template></paragraph><heading level='2'>Further reading</heading><list type='bullet'><listitem><template><target>cite journal</target><arg name="author"><space/>Jardetzky, O.<space/></arg><arg name="title"><space/>Studies on the Mechanism of Action of Chloramphenicol<space/></arg><arg name="journal"><space/>Journal of Biological Chemistry<space/></arg><arg name="volume"><space/>238<space/></arg><arg name="issue"><space/>7<space/></arg><arg name="pages"><space/>2498–2508<space/></arg><arg name="year"><space/>1963<space/></arg></template></listitem></list><heading level='2'>External links</heading><list type='bullet'><listitem><link type='external' href='http://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=CLM'>Chloramphenicol bound to proteins</link><space/>in the<space/><link><target>Protein Data Bank</target><part>PDB</part></link></listitem><listitem><template><target>MedlinePlusDrugInfo</target><arg>uspdi</arg><arg>202125</arg></template></listitem></list><paragraph><template><target>Antibiotics and chemotherapeutics for dermatological use</target></template><template><target>Gynecological anti-infectives and antiseptics</target></template><template><target>Amphenicols</target></template><template><target>Otologicals</target></template></paragraph><paragraph><template><target>Authority control</target></template></paragraph><paragraph><link><target>Category:Organochlorides</target></link><link><target>Category:Nitrobenzenes</target></link><link><target>Category:World Health Organization essential medicines</target></link><link><target>Category:IARC Group 2A carcinogens</target></link><link><target>Category:Halogen-containing natural products</target></link><link><target>Category:Diols</target></link><link><target>Category:Acetamides</target></link><link><target>Category:Phenethylamines</target></link><link><target>Category:Amphenicols</target></link><link><target>Category:Otologicals</target></link><link><target>Category:RTT</target></link></paragraph></article>